AstraZeneca
Compare AstraZeneca…UK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AstraZenecaUK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo.
Quarterly breakdown of revenue by product line and service category
2019-Q2 — 2023-Q2
Data from SEC filings via FMP • 4 periods available